Skip to main content
Log in

CANCER IMMUNOTHERAPY

Arming T cells to infiltrate pancreatic tumours

  • News & Views
  • Published:

From Nature Biomedical Engineering

View current issue Submit your manuscript

The efficacy of adoptive cell therapy for pancreatic cancer can be augmented by antigen-specific cytotoxic T cells genetically engineered to overexpress a C-X-C chemokine receptor whose ligand is highly expressed by pancreatic cancer cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Adoptively transferred T cells engineered to overexpress CXCR6 infiltrate and accumulate in the vasculature of pancreatic tumours.

References

  1. June, C. H. & Sadelain, M. N. Engl. J. Med. 379, 64–73 (2018).

    Article  CAS  Google Scholar 

  2. Grupp, S. A. et al. N. Engl. J. Med. 368, 1509–1518 (2013).

    Article  CAS  Google Scholar 

  3. Brentjens, R. J. et al. Sci. Transl. Med. 5, 177ra38 (2013).

    Article  Google Scholar 

  4. Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Cancer Cell 36, 471–482 (2019).

    Article  CAS  Google Scholar 

  5. Lesch, S. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-021-00737-6 (2021).

    Article  PubMed  Google Scholar 

  6. Davenport, A. J. et al. Cancer Immunol. Res. 3, 483–494 (2015).

    Article  CAS  Google Scholar 

  7. Morello, A., Sadelain, M. & Adusumilli, P. S. Cancer Discov. 6, 133–146 (2016).

    Article  CAS  Google Scholar 

  8. Beatty, G. L. et al. Gastroenterology 155, 29–32 (2018).

    Article  CAS  Google Scholar 

  9. Pastan, I. & Hassan, R. Cancer Res. 74, 2907–2912 (2014).

    Article  CAS  Google Scholar 

  10. Kachala, S. S. et al. Clin. Cancer Res. 20, 1020–1028 (2014); erratum 20, 3896 (2014).

  11. Servais, E. L. et al. Clin. Cancer Res. 18, 2478–2489 (2012).

    Article  CAS  Google Scholar 

  12. Cherkassky, L. et al. J. Clin. Invest. 126, 3130–3144 (2016).

    Article  Google Scholar 

  13. Adusumilli, P. S. et al. Sci. Transl. Med. 6, 261ra151 (2014).

    Article  Google Scholar 

  14. Adusumilli, P. S. et al. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-21-0407 (2021).

    Article  PubMed  Google Scholar 

  15. Brown, C. E. et al. N. Engl. J. Med. 375, 2561–2569 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Prasad S. Adusumilli.

Ethics declarations

Competing interests

P.S.A. has received research funding from ATARA Biotherapeutics and Acea Biosciences; has served on the scientific advisory boards of, or as a consultant for, ATARA Biotherapeutics, Bayer, Carisma Therapeutics, Imugene, ImmpactBio and Takeda Therapeutics; has pending patent applications on T-cell therapies; and has patents, royalties and intellectual property on mesothelin-targeted CARs and other T-cell therapies and on methods for the detection of cancer cells using viruses. L.C. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cherkassky, L., Adusumilli, P.S. Arming T cells to infiltrate pancreatic tumours. Nat Biomed Eng 5, 1243–1245 (2021). https://doi.org/10.1038/s41551-021-00821-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41551-021-00821-x

  • Springer Nature Limited

This article is cited by

Navigation